297 related articles for article (PubMed ID: 10939285)
21. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.
Guillemin GJ; Meininger V; Brew BJ
Neurodegener Dis; 2005; 2(3-4):166-76. PubMed ID: 16909022
[TBL] [Abstract][Full Text] [Related]
22. Central kynurenine pathway shift with age in women.
de Bie J; Guest J; Guillemin GJ; Grant R
J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
[TBL] [Abstract][Full Text] [Related]
23. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
24. 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells).
Saito K; Chen CY; Masana M; Crowley JS; Markey SP; Heyes MP
Biochem J; 1993 Apr; 291 ( Pt 1)(Pt 1):11-4. PubMed ID: 8471029
[TBL] [Abstract][Full Text] [Related]
25. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
26. Quinolinic acid in the pathogenesis of Alzheimer's disease.
Guillemin GJ; Williams KR; Smith DG; Smythe GA; Croitoru-Lamoury J; Brew BJ
Adv Exp Med Biol; 2003; 527():167-76. PubMed ID: 15206729
[TBL] [Abstract][Full Text] [Related]
27. Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha.
Pemberton LA; Kerr SJ; Smythe G; Brew BJ
J Interferon Cytokine Res; 1997 Oct; 17(10):589-95. PubMed ID: 9355959
[TBL] [Abstract][Full Text] [Related]
28. The role of kynurenine pathway and kynurenic aminotransferase alleles in postpartum depression following cesarean section in Chinese women.
Quan C; Wang S; Duan K; Ma J; Yu H; Yang M; Hu N; Long G; Zeng G; Huang Z
Brain Behav; 2020 Apr; 10(4):e01566. PubMed ID: 32101387
[TBL] [Abstract][Full Text] [Related]
29. Kynurenine pathway metabolism in human astrocytes.
Guillemin GJ; Kerr SJ; Smythe GA; Armati PJ; Brew BJ
Adv Exp Med Biol; 1999; 467():125-31. PubMed ID: 10721049
[TBL] [Abstract][Full Text] [Related]
30. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
31. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease.
Ting KK; Brew BJ; Guillemin GJ
J Neuroinflammation; 2009 Dec; 6():36. PubMed ID: 20003262
[TBL] [Abstract][Full Text] [Related]
32. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
33. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase.
Chiarugi A; Moroni F
Neuropharmacology; 1999 Aug; 38(8):1225-33. PubMed ID: 10462134
[TBL] [Abstract][Full Text] [Related]
34. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
35. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
Guidetti P; Wu HQ; Schwarcz R
Exp Neurol; 2000 May; 163(1):123-30. PubMed ID: 10785450
[TBL] [Abstract][Full Text] [Related]
36. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures.
Heyes MP; Saito K; Devinsky O; Nadi NS
Epilepsia; 1994; 35(2):251-7. PubMed ID: 8156942
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections.
Ceresoli G; Guidetti P; Schwarcz R
Brain Res Dev Brain Res; 1997 May; 100(1):73-81. PubMed ID: 9174248
[TBL] [Abstract][Full Text] [Related]
38. Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease.
Lim CK; Fernández-Gomez FJ; Braidy N; Estrada C; Costa C; Costa S; Bessede A; Fernandez-Villalba E; Zinger A; Herrero MT; Guillemin GJ
Prog Neurobiol; 2017 Aug; 155():76-95. PubMed ID: 27072742
[TBL] [Abstract][Full Text] [Related]
39. Peripheral and central kynurenine pathway abnormalities in major depression.
Paul ER; Schwieler L; Erhardt S; Boda S; Trepci A; Kämpe R; Asratian A; Holm L; Yngve A; Dantzer R; Heilig M; Hamilton JP; Samuelsson M
Brain Behav Immun; 2022 Mar; 101():136-145. PubMed ID: 34999196
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages.
Chiarugi A; Calvani M; Meli E; Traggiai E; Moroni F
J Neuroimmunol; 2001 Nov; 120(1-2):190-8. PubMed ID: 11694334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
